Finn
TEVA Pharmaceuticals · Generic drugs · Neuroscience · Turnaround · Thesis updated November 15, 2026

Austedo and new approvals accelerate Teva's growth turnaround

01 Running thesis

The turnaround gains external validation

Teva is transitioning from a slow-growth generic drug company to a mix of generics, biosimilars, and higher-margin branded medicines. Q3 2026 results accelerated this narrative. Austedo hit its $2.5 billion sales target a year ahead of schedule, and the FDA approved Weltruza. Strong growth across the branded portfolio prompted management to raise full-year guidance for its key assets.

This growth matters because Teva is losing a massive stream of revenue from generic Revlimid, with management expecting about $1.1 billion of pressure in 2026. The bull case is that Teva can use its newer branded drugs, growing biosimilars, and cost savings to keep growing while margins improve, fully covering the Revlimid gap. The biosimilar segment achieved its $800 million goal a year early.

The pipeline also took steps forward. Teva acquired BXCL501 from BioXcel for acute agitation, strengthening its psychiatric portfolio. It also discontinued the emrusolmin Phase II study after an interim futility analysis, focusing resources on higher-probability assets like ecopipam and duvakitug.

The bear case notes that the core generics business remains somewhat soft without Revlimid. If Austedo slows down due to channel inventory changes or IRA pricing impacts in 2027, the growth engine could stall. An October 2026 U.S. tariff agreement protects some innovative drugs, but generic products still face tariff uncertainty. The FTC review of inhaler patents and a restarted TAPI sale also add risk.

Nov 2026▲Q3 2026 highlighted strong commercial execution, with Austedo hitting its $2.5 billion target a year early and the FDA approval of Weltruza. Teva also reached a tariff agreement with the U.S. Administration for certain innovative products.
Jul 2026▲Q2 2026 results prompted a guidance raise for key innovative drugs. Fitch upgraded Teva to investment grade, and the company closed its Emalex acquisition.
Apr 2026▲Q1 2026 revenue was $4.0 billion, up 4%, and non-GAAP EPS was $0.53. Strong growth from Austedo, Ajovy, and Uzedy made the turnaround case more convincing.
Apr 2026▲The Q1 2026 filing showed U.S. Austedo revenue up 41%, Ajovy up 64%, and Uzedy up 62%. Teva also agreed to acquire Emalex Biosciences for $700 million.
Feb 2026→The 2025 Form 10-K confirmed strong U.S. growth and weak Europe and International results. It also added the FTC inhaler patent investigation as a clear risk.
Jan 2026▲Full-year 2025 results showed Austedo, Uzedy, and Ajovy growing strongly, while net debt to EBITDA improved to 2.5x. Management also quantified about $1.1 billion of 2026 pressure from generic Revlimid.
Nov 2025▼Exclusive talks to sell TAPI ended, delaying a key debt reduction catalyst. U.S. operations stayed strong, but the sale process became less certain.
02 Business model

Generics scale meets branded drugs

Teva makes money by selling prescription medicines. A large part of the company is generic drugs, which are lower-cost versions of branded drugs after exclusivity ends. This business benefits from global distribution and a massive product catalog, but it faces constant pricing pressure.

The newer growth side is branded medicine. Austedo, Ajovy, Uzedy, and the newly approved Weltruza have patent protection and stronger pricing power. That product mix shift is the core of Teva's growth plan.

Teva also sells biosimilars, which are close copies of complex biologic drugs. The company now has 15 products on the market, turning the category into a major growth pillar. The pipeline includes duvakitug, DARI, and ecopipam. These represent options on future growth.

The balance sheet is recovering, though financial health remains a vulnerability. Selling TAPI, its active pharmaceutical ingredient business, would help reduce debt further. The first exclusive talks ended in 2025, and a renewed sale process is currently under way.

03 Product portfolio

The drugs that matter most

Growth engine

Austedo

Austedo is Teva's most important growth drug, hitting its $2.5 billion target a year early in Q3 2026.

Growth engine

Ajovy

Ajovy treats migraine prevention. It continues to grow and outperform internal expectations.

Growth engine

Uzedy and Weltruza

Uzedy and Weltruza are long-acting injectable schizophrenia medicines that give Teva a highly competitive psychiatric franchise.

Cash cow

Global generics

Generics remain Teva's broad base business. The segment is stable when excluding the steep Revlimid decline.

Option

Biosimilars

Biosimilars bridge generics and branded drugs. Teva now has 15 products in the market and hit its $800 million goal a year early.

Option

Ecopipam

Teva submitted the ecopipam application in June 2026 for pediatric Tourette syndrome, with FDA action expected in early 2027.

Option

Duvakitug

Duvakitug is an anti-TL1A asset in Phase 3 trials, recently expanded into hidradenitis suppurativa and Crohn's disease.

04 Business segments

U.S. growth carries the mix

United States53%growing fast
Europe29%declining
International Markets13%declining
Other Activities including TAPI5%declining

The segment mix uses full-year 2025 revenue from Teva's 2025 Form 10-K. The United States is the clear growth center.

05 Risk factors

What could break the setup

Revlimid cliff overwhelms growth

High impact · Medium odds

Teva faces about $1.1 billion of 2026 revenue pressure from lower generic Revlimid sales. Management expects newer medicines to cover this gap. If they fall short, overall revenue growth targets are at risk.

We watchTrack quarterly U.S. revenue for Austedo, Ajovy, Uzedy, and generic lenalidomide capsules.

Austedo slows

High impact · Medium odds

Austedo is the largest growth engine. Elevated channel inventory could disrupt near-term revenue, and the IRA implementation in 2027 could pressure pricing. Any sharp slowdown would weaken the peak sales case.

We watchWatch Austedo quarterly U.S. revenue growth and any updates on 2027 IRA price negotiation effects.

Tariff uncertainty on generics

Medium impact · Medium odds

While Teva reached a U.S. agreement in late 2026 to protect specific innovative products from tariffs, the broader generic and non-patented portfolio remains exposed to policy changes. Broad tariffs could squeeze generic margins.

We watchMonitor U.S. trade policy announcements and Teva's updates on generic gross margin impacts.

TAPI sale slips again

Medium impact · Medium odds

Teva wants to sell TAPI, its active pharmaceutical ingredient business, to help reduce debt. Exclusive talks ended in 2025, and a renewed sale process began. A weak price or no deal would slow balance sheet repair.

We watchWatch for a signed TAPI sale agreement, the sale price, and the expected closing date.

FTC inhaler patent action

Medium impact · Medium odds

The FTC is investigating Teva's Orange Book patent listings for certain inhaler products. An adverse result could mean legal costs, penalties, or faster generic competition.

We watchMonitor FTC statements, court filings, settlements, and any change in inhaler generic competition.
06 Quick answers

In one breath

What does Teva Pharmaceutical do?

Teva sells prescription drugs around the world. It is best known for generic drugs, but its growth now depends more on branded medicines like Austedo, Ajovy, and Uzedy.

Why is Revlimid important for Teva?

Teva sells a generic version of Revlimid, called lenalidomide capsules. That revenue is falling in 2026, and management has pointed to about $1.1 billion of pressure from the decline.

What is the main bull case for TEVA stock?

The bull case is that Teva's newer branded medicines keep growing fast enough to cover the Revlimid decline. If that happens while debt falls and margins rise, the turnaround gets more credible.

What is the biggest risk for Teva?

The biggest near-term risk is that growth drugs do not fully cover the 2026 Revlimid headwind. The TAPI sale and the FTC inhaler patent probe are also important risks to watch.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 15, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Teva Q3 2026 earnings transcript
  2. Teva Q3 2026 Form 10-Q
  3. Teva 2025 Form 10-K
08 Explore the industry

Comparable Drug Manufacturers - Specialty & Generic companies

Companies near Teva Pharmaceutical Industries Limited in Finn's Drug Manufacturers - Specialty & Generic industry ranking.

Get started with Finn today